PCM
VTVT icon

Prelude Capital Management’s vTv Therapeutics VTVT Stock Holding History

Prelude Capital Management’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-285
Closed -$57K – 1924
2017
Q2 		$57K Hold
285
– – 0.01% 964
2017
Q1 		$75K Buy
+285
New +$65K 0.01% 876

Other funds holding VTVT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Prelude Capital Management's VTVT Position: Q3 2017 in Review

Prelude Capital Management sold out of vTv Therapeutics (VTVT) in Q3 2017, closing a stake of 285 shares — an estimated $57K sold.

Prelude Capital Management first reported a position in VTVT in Q1 2017 and held it in 2 quarters. The position peaked at $75K in Q1 2017. 37 funds tracked by Wall St. Rank hold VTVT as of Q3 2017.

  • Prelude Capital Management reported no remaining vTv Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Prelude Capital Management sold 285 vTv Therapeutics shares in Q3 2017, an estimated $57K.
  • Prelude Capital Management first reported a position in vTv Therapeutics in Q1 2017 and held it in 2 quarters.
  • Prelude Capital Management's vTv Therapeutics position peaked at $75K in Q1 2017.
  • 37 funds tracked by Wall St. Rank held vTv Therapeutics as of Q3 2017.

Based on Prelude Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.